Saurabh Zanwar, MD, Mayo Clinic, Rochester, MN, gives an overview of unmet needs that remain for patients with light chain (AL) amyloidosis who fail frontline therapy, commenting on the lack of randomized clinical trial data in this space. This interview took place at the XIX International Symposium on Amyloidosis (ISA) in Rochester, MN.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.